EC clears GSK’s Benlysta for lupus nephritis
The drug is the only biologic treatment approved in Europe that is specifically designed to work in systemic lupus erythematosus and lupus nephritis
Read More
Tag: lupus nephritis
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
